A meta-analysis of 25 randomized clinical trials, involving nearly 15,000 premenopausal women with HR+ breast cancer, also demonstrated that ovarian ablation or ovarian function suppression using GnRH significantly reduced the 15-year risk of recurrence and mortality [82]. This evidence concerns the gene GNRH1 and breast cancer.